Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04041037 · ClinicalTrials.gov registry record
The Management of Pilonidal Wounds With ACell MicroMatrix® and Cytal® Wound Matrix: A Case Series
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04041037: Clinical Trial study, sponsored by Integra LifeSciences Corporation.
NCT04041037 is a clinical trial that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04041037 was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
A case series involving the concomitant use of MicroMatrix® and Cytal® Wound Matrix 2-Layer with standard of care negative pressure wound therapy (NPWT) during the management of pilonidal wound healing.
Primary Outcome
The study was terminated by Sponsor; no outcome measure data analyses were conducted.
Interventions
- DEVICE Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2019-11-05 |
Why NCT04041037 stopped before completion
NCT04041037 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix is the first listed.
NCT04041037 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04041037 about?
NCT04041037 is a clinical study titled "The Management of Pilonidal Wounds With ACell MicroMatrix® and Cytal® Wound Matrix: A Case Series". A case series involving the concomitant use of MicroMatrix® and Cytal® Wound Matrix 2-Layer with standard of care negative pressure wound therapy (NPWT) during the management of pilonidal wound healing.
What is the current status of trial NCT04041037?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-03-26. Estimated completion is 2019-11-05.
What interventions are being tested in trial NCT04041037?
The interventions under investigation include: Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix (DEVICE).
Who is sponsoring clinical trial NCT04041037?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI